Lyell Immunopharma, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; unaudited. Lyell is a clinical-stage cell therapy company developing treatments for solid tumors. It has no products approved for sale and has not generated product-sales revenue.
Financial results and liquidity
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Revenue | $0.003 million | $0.065 million |
| Research and development expense | $43.2 million | $44.6 million |
| General and administrative expense | $13.5 million | $19.3 million |
| Loss from operations | $55.6 million | $62.6 million |
| Net loss | $60.7 million | $67.0 million |
| Net loss per share, basic and diluted | $0.24 | $0.27 |
| Net cash used in operating activities | $42.0 million | $46.2 million |
At March 31, cash and cash equivalents were $125.7 million and marketable securities were $400.7 million, totaling $526.3 million in cash resources as reported by management. Total assets were $694.2 million; total liabilities were $91.1 million. The company had no debt outstanding. Operating lease liabilities totaled $61.8 million.
Management believes available cash, cash equivalents and marketable securities will fund operations for at least 12 months from issuance of the financial statements and, under its current operating plan, into 2027. The company reported a $60.7 million accumulated quarterly loss and expects further losses.
Changes versus the prior-year quarter
- Net loss narrowed by $6.3 million, while operating loss narrowed by $7.0 million, primarily reflecting lower personnel-related costs and G&A stock-based compensation following the November 2023 workforce reduction.
- R&D expense declined $1.5 million, as lower personnel costs were partly offset by higher research, clinical-trial and success-payment costs.
- Net cash used in operations improved by $4.2 million.
- Interest income increased $2.3 million to $6.8 million, primarily due to higher interest rates.
- Investment impairment expense increased to $13.0 million from $10.0 million. The 2024 charge fully impaired one strategic investment after anticipated funding was not secured within the expected timeframe.
Revenue is immaterial, so a revenue-based operating margin is not informative. The filing does not present a meaningful product gross margin.
Outlook, risks and notable items
- LYL797 and LYL845 are in Phase 1 trials; initial LYL797 data from at least 20 patients were expected in the first half of 2024, and initial LYL845 clinical and translational data were expected in the second half of 2024. LYL119 was in preclinical development, with an IND submission expected in the first half of 2024.
- The company may sell up to $150 million of common stock through an at-the-market agreement; no shares had been sold under it as of the filing. Future equity financing could dilute existing shareholders.
- Success-payment agreements with Fred Hutch and Stanford could require aggregate payments of up to $400 million if specified stock-price thresholds are met. No payment had been triggered as of March 31, 2024; recorded success-payment liabilities totaled $2.5 million.
- Key risks include clinical and regulatory uncertainty, patient enrollment and retention, complex cell-therapy manufacturing and supply-chain dependencies, reliance on third parties, competition, and the potential need for additional capital. Management also cites macroeconomic and market volatility.
- Other unusual items: Q1 2024 included a $13.0 million non-cash investment impairment and $9.2 million of stock-based compensation. Management reported disclosure controls effective at a reasonable assurance level and no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether clinical-trial updates and the anticipated LYL119 IND submission occurred on the stated timelines, and what the data show on safety and efficacy.
- Whether the stated cash runway into 2027 remains supported by spending, trial plans and manufacturing commitments.
- Whether the ATM facility is used, the resulting dilution, and any other financing needs.
- Changes in strategic-investment values, success-payment liabilities and potential contingent obligations.
- Clinical manufacturing capacity, reliability and costs, as well as enrollment progress and competition in target indications.